A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC) - Peterson, L M; Kurland, B F; Schubert, E K (Mol Imaging Biol, 2014)